Category Archives: Medicine

Pregnancy as a Window to Future Health – SMFM White Paper

The development of complications in pregnancy provides a new window of opportunity for early heart disease risk screening and intervention for women.

How Pregnancy Provides a Window to Future Health and Eliminating Some Chronic Disease

Physicians with the Society for Maternal-Fetal Medicine released a paper today that provides significant insight into future health conditions that women are likely to experience, and that can be detected early based on information relating to the course of pregnancy.  The paper, Pregnancy as a Window to Future Health: The development of complications in pregnancy provides a new window of opportunity for early heart disease risk screening and intervention for women, acknowledges that, for most women, the demands of pregnancy on the cardiovascular and metabolic systems are some of the highest the body will endure.

Comprehensive Maternal Hemorrhage Protocols Improve Patient Safety

In a study to be presented on February 16 between 8 a.m., and 10 a.m. PST, at the Society for Maternal-Fetal Medicine’s annual meeting, The Pregnancy Meeting ™, in San Francisco, researchers will report findings that suggest comprehensive maternal hemorrhage protocols reduce utilization of blood products and improve patient safety.

MOD Award Abstract: Study Shows Progesterone Shots Do Not Reduce Preterm Delivery in Twin Pregnancies

In a study to be presented on February 14 between 8 a.m. and 10 a.m. PST, at the Society for Maternal-Fetal Medicine’s 33rd annual meeting, The Pregnancy Meeting ™, researchers will report findings that suggest that 17P, a form of progesterone, is not effective in preventing preterm birth among women with twin pregnancies — and may possibly be harmful.

REVISED: Preemptive Treatment of Severe Morning Sickness Decreases Suffering for Moms-to-Be

In a study to be presented on February 14 between 1:15 p.m., and 3:30 p.m. PST, at the Society for Maternal-Fetal Medicine’s annual meeting, The Pregnancy Meeting ™, in San Francisco, California, researchers will present data showing the effectiveness of preemptive treatment for hyperemesis gravidarum and severe morning sickness.

Study Finds That Anti-diabetic Medication Can Prevent the Long Term Effects of Maternal Obesity

Full abstract at the bottom of the page. Click Here to view all 2012 abstracts.

Study Finds That Anti-diabetic Medication Can Prevent the Long Term Effects of Maternal Obesity

In a study to be presented today at the Society for Maternal-Fetal Medicine’s annual meeting, The Pregnancy Meeting ™, in Dallas, Texas, researchers will report findings that show that short therapy with the anti-diabetic medication Pioglitazone can prevent the long term effects of maternal obesity on offspring.

Study Finds Residence in U.S. a Risk Factor for Preterm Birth

Full abstract at the bottom of the page. Click Here to view all 2012 abstracts.

Study Finds Residence in U.S. a Risk Factor for Preterm Birth

 In a study to be presented today at the Society for Maternal-Fetal Medicine’s annual meeting, The Pregnancy Meeting ™, in Dallas, Texas, researchers will report findings that indicate that duration of stay in the United States is associated with increased risk of preterm birth for Hispanic women.

Study Finds Some Medications May Interact with Common Anti- Recurrent Preterm Birth Medication

Full abstract at the bottom of the page. Click Here to view all 2012 abstracts.

Study Finds Some Medications May Interact with Common Anti- Recurrent Preterm Birth Medication

In a study to be presented today at the Society for Maternal-Fetal Medicine’s annual meeting, The Pregnancy Meeting ™, in Dallas, Texas, researchers will report findings that indicate that prescription medications may affect the body’s ability to metabolize 17-alpha-hydroxyprogesterone caproate (17-OHPC), the only FDA approved medication for the prevention of recurrent preterm birth.

2011: Society for Maternal-Fetal Medicine commends senators on letter to KV Pharmaceutical Company

Letter Urges Manufacturer to Drop Pricing of Makena

The Society for Maternal-Fetal Medicine weighed in on a recent letter sent by members of the United States Senate Committee on Health, Education, Labor, and Pensions to Greg Divis and Terry Hatfield with KV Pharmaceutical Company. Divis is the company’s CEO and Hatfield is chairman of the board of directors. Senators Harkin, Mikulski, Murray, Sanders, Casey, Franken, Whitehouse, and Blumenthal each signed the letter requesting the company to lower the price of Makena.

Letter: Senate Committee on Health, Education, Labor, and Pensions to KV Pharmaceuticals

Mssrs. Divis and Hatfield,

We join together today to call on KV Pharmaceuticals to lower the price of Makena, your newly-approved drug used to prevent pre-term birth

Prior to Makena’s approval, the same progesterone treatment was widely available through compounding pharmacies for $10 – $20 per dose. We note your price reduction from the original, shocking, $1,500 to per does to the current list price of $690 per dose as a step in the right direction. At approximately $10,000 for a course of treatment, however, the new price still poses an unreasonable burden on patients and the healthcare system.

2011: Society for Maternal-Fetal Medicine commends FDA on Makena announcement

FDA Announcement Allows Continued Compounding of Drug

The Society for Maternal-Fetal Medicine (SMFM) weighed in on today’s FDA announcement to continue to allow pharmacies to compound hydroxyprogesterone caproate, also known as 17P. This FDA announcement comes in response to an outcry from SMFM, ACOG and others regarding the costs of the just-released pharmaceutical version of the drug. The new drug, Makena, made by KV Pharmaceuticals, is being sold at $1,500 per dose as opposed to the pharmacy compound which typically costs $10 to $20 per dose.

2011: Society for Maternal-Fetal Medicine strongly opposes skyrocketing increase in cost of drug proven to prevent preterm labor in high-risk pregnancies

The Society for Maternal-Fetal Medicine (SMFM) announced today strong opposition to KV Pharmaceutical’s recent pricing of its drug “Makena.” SMFM represents more than 2,000 physicians who have specialized training in maternal-fetal medicine and work with high-risk pregnancies where drugs such as Makena are often prescribed. The drug, designed to prevent preterm pregnancies is being sold at $1,500 per dose. Makena, which has been produced as compound 17-hydroxyprogesterone by compounding pharmacies for several years, has typically cost $10 to $20 per dose.

2011: Study finds that folate does not offer protection against preterm delivery

In a study to be presented today at the Society for Maternal-Fetal Medicine’s (SMFM) annual meeting, The Pregnancy Meeting ™, in San Francisco, researchers will present findings that show that folate intake before and during pregnancy does not protect Norwegian women against spontaneous preterm delivery.

2011: Study finds that use of magnesium sulfate may offer protection from cerebral palsy induced by maternal inflammation

In a study to be presented today at the Society for Maternal-Fetal Medicine’s (SMFM) annual meeting, The Pregnancy Meeting ™, in San Francisco, researchers will present findings that showed that in rats, the use of magnesium sulfate (Mg) significantly reduced the neonatal brain injury associated with maternal inflammation or maternal infection.

2011: Study finds that use of 17-Hydroxyprogesterone does not reduce the rate of preterm delivery or neonatal complications in twins

In a study to be presented today at the Society for Maternal-Fetal Medicine’s (SMFM) annual meeting, The Pregnancy Meeting ™, in San Francisco, researchers will present findings that show that the use of the hormone 17-Hydroxyprogesterone does not reduce the rate of preterm delivery or neonatal complications in twins.

2011 March of Dimes Award Abstract: New research helps explain how progesterone prevents preterm birth

Research presented today at the 31st Annual meeting of the Society for Maternal-Fetal Medicine (SMFM) ― The Pregnancy Meeting™ has found that three proteins known as XIAP, BID, and Bcl-2 are responsible in part for the success of progesterone treatments in the prevention of preterm labor. They may also play an important role in triggering normal labor.

Powered by WordPress | Designed by: seo service | Thanks to seo company, web designers and internet marketing company